BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 19584962)

  • 1. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.
    Nakao K; Mochizuki H
    Drugs Today (Barc); 2009 May; 45(5):323-9. PubMed ID: 19584962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Profiles of Nalfurafine Hydrochloride for the Treatment of Pruritus Patients.
    Miyamoto Y; Oh T; Aihara E; Ando A
    Handb Exp Pharmacol; 2022; 271():455-472. PubMed ID: 33201326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a new kappa-opioid receptor agonist for the treatment of uremic pruritus.
    Delmez JA
    Nat Clin Pract Nephrol; 2006 Jul; 2(7):358-9. PubMed ID: 16932462
    [No Abstract]   [Full Text] [Related]  

  • 4. Nalfurafine hydrochloride for the treatment of pruritus.
    Inui S
    Expert Opin Pharmacother; 2012 Jul; 13(10):1507-13. PubMed ID: 22663138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.
    Kumagai H; Ebata T; Takamori K; Muramatsu T; Nakamoto H; Suzuki H
    Nephrol Dial Transplant; 2010 Apr; 25(4):1251-7. PubMed ID: 19926718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.
    Phan NQ; Lotts T; Antal A; Bernhard JD; Ständer S
    Acta Derm Venereol; 2012 Sep; 92(5):555-60. PubMed ID: 22504709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological and clinical profiles of nalfurafine hydrochloride (Remitch) capsules 2.5 microg) , a new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients].
    Nakao K; Ando A; Hirakata M; Ando N; Takeshita K; Miyamoto Y; Mochizuki H
    Nihon Yakurigaku Zasshi; 2010 May; 135(5):205-14. PubMed ID: 20467170
    [No Abstract]   [Full Text] [Related]  

  • 8. One year long-term study on abuse liability of nalfurafine in hemodialysis patients.
    Ueno Y; Mori A; Yanagita T
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):823-31. PubMed ID: 24040851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies.
    Wikström B; Gellert R; Ladefoged SD; Danda Y; Akai M; Ide K; Ogasawara M; Kawashima Y; Ueno K; Mori A; Ueno Y
    J Am Soc Nephrol; 2005 Dec; 16(12):3742-7. PubMed ID: 16251241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
    Schattauer SS; Kuhar JR; Song A; Chavkin C
    Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo pharmacological characterization of the main metabolites of nalfurafine hydrochloride.
    Nakao K; Togashi Y; Honda T; Momen S; Umeuchi H; Sakakibara S; Tanaka T; Okano K; Mochizuki H
    Eur J Pharmacol; 2012 Nov; 695(1-3):57-61. PubMed ID: 22981641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
    Nakao K; Hasebe K; Yoshikawa S; Ikeda K; Hirakata M; Miyamoto Y; Mochizuki H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):185-91. PubMed ID: 21226314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
    Yagi M; Tanaka A; Namisaki T; Takahashi A; Abe M; Honda A; Matsuzaki Y; Ohira H; Yoshiji H; Takikawa H;
    J Gastroenterol; 2018 Oct; 53(10):1151-1158. PubMed ID: 29663077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats.
    Inan S; Cowan A
    Pharmacol Biochem Behav; 2006 Sep; 85(1):39-43. PubMed ID: 16919318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients.
    Kumagai H; Ebata T; Takamori K; Miyasato K; Muramatsu T; Nakamoto H; Kurihara M; Yanagita T; Suzuki H
    Am J Nephrol; 2012; 36(2):175-83. PubMed ID: 22868684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uremic pruritus.
    Mettang T; Kremer AE
    Kidney Int; 2015 Apr; 87(4):685-91. PubMed ID: 24402092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
    Kamimura K; Yokoo T; Kamimura H; Sakamaki A; Abe S; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
    PLoS One; 2017; 12(6):e0178991. PubMed ID: 28604788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.
    Lazenka ML; Moerke MJ; Townsend EA; Freeman KB; Carroll FI; Negus SS
    Psychopharmacology (Berl); 2018 Jan; 235(1):203-213. PubMed ID: 29063139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis].
    Nakao K; Ikeda K; Kurokawa T; Togashi Y; Umeuchi H; Honda T; Okano K; Mochizuki H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Apr; 28(2):75-83. PubMed ID: 18516986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride.
    Umeuchi H; Kawashima Y; Aoki CA; Kurokawa T; Nakao K; Itoh M; Kikuchi K; Kato T; Okano K; Gershwin ME; Miyakawa H
    Eur J Pharmacol; 2005 Aug; 518(2-3):133-9. PubMed ID: 16055114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.